Dear customers, partners, mentors, dear friends. The year of 2014 is nearing to its end and we want to use the chance to thank you for your support. The year 2014 was for all of us full with challenges, new inventions and happy moments. Today [...]
The congress "Partnership in Clinical Trials" (PCT) will unite again the experts from the pharmaceutical industry and promote the future industrial partnerships. Cyntegrity is participating at PCT in the sessions and discussions about risk-based monitoring (RbM) as a research company, the mission and main focus [...]
On 20th of November 2014 Cyntegrity presents the solutions for effective risk-based monitoring and clinical data quality on the conference Pharma forum. The Pharma Forum occurs this year in the capital of the German state of Saarland in Saarbruecken on the 20th of November 2014. [...]
Pharmaceutical companies often face staff and management resistance beyond other difficulties to embrace technological innovation. Processes are established and bonded to the internal and usual practice of staff members. To no surprise, risk-based monitoring is not a different case. Therefore, in order to make the [...]
Subject enrolment: Creating Effective Enrolment Models Highlights of On-Demand Webinar The topic of clinical trial subject enrollment has been addressed, debated, analyzed and implemented in many forms; nevertheless, study teams still face ongoing challenges with subject enrollment. Although study sites are often blamed for sluggish [...]
The software solution EarlyBird targets data anomalies on the early stages of the clinical trials and increases the data quality. High clinical data quality reduces monitoring costs, secures the FDA/EMA approval with higher resolution of the clinical effect.
Average clinical trials Submissions in 2013: Phase I - 314 studies per Quartile, phase II - 233 studies per Quartile, Phase III - 237 studies per Quartile; R&D Spending in Pharma goes down by 5% in 2013 and in Generics jumps by 18%: Major partnership: [...]
